16: One of the most-anticipated FDA decisions of the first half of 2024 came early as the regulator approved Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy (exagamglogene autotemcel) as a one-time treatment for transfusion-dependent beta-thalassemia (TDT)
Next, over a 14-day period, the early hepatic organoids were directed to a mature liver-like stage
According to the coverage of abnormal liver cells, liver injuries were graded as follows: Level 0, normal, no liver cell degeneration
For manual annotation, we obtained markers using the FindClusters function from Seurat (Supplementary Data File 1 Top 50 cell markers in each cluster ) and we observed cell-type-specific expression of a number of genes (Fig
This ensures you receive the safest, most effective treatment
Para continuar, ingresa atu cuenta trace-id: e0b14daa-5a8d-4a31-802c-48e46501a82a Usamos cookies para mejorar tu experiencia en Mercado Libre